<DOC>
	<DOCNO>NCT02232321</DOCNO>
	<brief_summary>Objectives To investigate effect achieve minimal disease activity ( MDA ) use protocolized treatment strategy progression subclinical atherosclerosis arterial stiffness psoriatic arthritis ( PsA ) patient . Hypothesis Effective suppression inflammation patient achieve MDA less progression subclinical atherosclerosis arterial stiffness patient achieve MDA mean standardized treatment algorithm aim MDA . Design subject One hundred consecutive PsA patient participate 2-year prospective , hospital-based , cohort study . Interventions All participant receive 2-year tight-control treatment . Treatment adjust accord standardize protocol base European League Against Rheumatism ( EULAR ) recommendation Hong Kong guideline use biologics every 4-monthly aiming MDA . Study instrument Carotid intima-media thickness ( IMT ) measure use high-resolution ultrasound . Arterial stiffness measure use pulse wave velocity ( PWV ) dedicate tonometry system augmentation index ( AIx ) SphygmoCor device . Main outcome measure analysis The main outcome measure change IMT period 2 year compare patient achieve MDA 12 month ( MDA group ) achieve MDA ( non-MDA group ) . Secondary outcome include difference change AIx PWV 2 year 2 group . Comparisons change IMT , AIx PWV 2 year MDA non-MDA group perform .</brief_summary>
	<brief_title>Vascular Effects Achieving Minimal Disease Activity Psoriatic Arthritis - 2 Year Prospective Cohort Study</brief_title>
	<detailed_description>Background : Patients psoriatic arthritis ( PsA ) experience substantial morbidity unfavorable outcomes referral center . Although study all-cause mortality yield mixed result , increase cardiovascular ( CV ) mortality morbidity PsA consistently report . Data group others show underlie high CV disease ( CVD ) rate great burden subclinical carotid atherosclerosis . Increased intima-media thickness ( IMT ) significantly correlate traditional risk factor disease-related parameter . An increased prevalence arterial stiffness also demonstrate patient psoriasis PsA compare control . In PsA , criterion minimal disease activity ( MDA ) develop validate . These criterion use 7 measurement include entheseal skin assessment . Achieving MDA criterion result less radiographic damage long term . The development instrument step toward 'treatment target ' PsA . MDA achieve 48-60 % patient ≥ 1 visit , sustain ≥ 12 month ( sustain MDA ) least one third PsA patient large observational cohort . While achieve MDA may result significant benefit articular disease , little known effect extra-articular disease , include CVD risk . The use surrogate end point instead actual CV event may provide evidence whether PsA patient may benefit potent anti-inflammatory treatment prevention premature atherosclerosis . Data group others link suppression inflammation use anti-tumour necrosis factor ( anti-TNF ) favourable effect CV surrogate maker , include carotid IMT arterial stiffness . More recently , tight-control treatment strategy aim remission effective improve arterial stiffness early rheumatoid arthritis ( RA ) cohort . There imperative need interventional trial CV end point investigate whether achievement MDA protocolized treatment strategy could reduce CVD risk PsA . To fill gap knowledge , propose prospective cohort study ascertain whether achieve MDA protocolized treatment strategy may prevent long term progression IMT arterial stiffness great extent achieve MDA patient PsA . Aim study : Primary outcome : 1 . Effect achieve MDA ( MDA group ) 12 month progression subclinical atherosclerosis period 24 month evaluate IMT compare achieve MDA ( non-MDA group ) Secondary outcome : 1 . Changes arterial stiffness period 24 month evaluate pulse wave velocity ( PWV ) augmentation Index ( AIx ) MDA group non-MDA group . 2 . The proportion patient achieve sustain MDA ( 12 24 month ) 3 . Changes IMT arterial stiffness period 24 month evaluate IMT , PWV AIx patient achieve sustain MDA achieve sustain MDA . 4 . Correlations change IMT , PWV , AIX change marker disease activity Hypothesis : Effective suppression inflammation PsA patient achieve MDA less progression subclinical atherosclerosis arterial stiffness patient achieve MDA mean protocolized treatment algorithm</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Arthritis , Psoriatic</mesh_term>
	<criteria>PsA attend outpatient clinic Prince Wales Hospital ( PWH ) fulfil Classification Psoriatic Arthritis criterion 1 ) history overt CVD ( myocardial infarction , percutaneous transluminal coronary angioplasty , surgery ischemic heart disease , stroke , transient ischemic attack , carotid endarterectomy , peripheral arterial reconstructive surgery , limb amputation ) , 2 ) aspirin , HMGCoA reductase inhibitor ( statin ) angiotensinconvertingenzyme inhibitor ( ACEI ) , 3 ) significant comorbidities include severe renal impairment define glomerular filtration rate le 30 mL/min/1.73m2 , alanine aminotransferase ( ALT ) ≥2xULN , hemoglobin level &lt; 8.5gm/dl , white blood cell count &lt; 3.5x109/liter , platelet count &lt; 100x109/liter , 4 ) female childbearing potential unwilling use adequate contraception , pregnant breastfeed woman , 5 ) glucocorticoid dose &gt; 10mg/day ( equivalent dose prednisolone )</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>